(3S,3'S,5R,5'R)-3,3'-二羟基-kappa,kappa-胡罗卜素-6,6'-二酮 | 470-38-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: (3S,3'S,5R,5'R)-3,3'-二羟基-kappa,kappa-胡罗卜素-6,6'-二酮
• 中文别名: 辣椒紫紅素
• 英文名称: capsorubin
• 英文别名: (all-E,3S,3'S,5R,5'R)-3,3'-dihydroxy-κ,κ-carotene-6,6'-dione；(3S,3'S,5R,5'R)-3,3'-dihydroxy-κ,κ-carotene-6,6'-dione；(3S,5R,3'S,5'R)-3,3'-dihydroxy-κ,κ-carotene-6,6'-dione；(3S,5R,3'S,5'R)-3,3'-Dihydroxy-κ,κ-carotin-6,6'-dion；all-trans-Capsorubin；(2E,4E,6E,8E,10E,12E,14E,16E,18E)-1,20-bis[(1R,4S)-4-hydroxy-1,2,2-trimethylcyclopentyl]-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaene-1,20-dione
• CAS: 470-38-2
• 化学式: C₄₀H₅₆O₄
• 分子量: 600.882
• InChiKey: GVOIABOMXKDDGU-YUURSNASSA-N

物化性质

• 熔点：
  201 °C
• 沸点：
  741.8±60.0 °C(Predicted)
• 密度：
  1.016±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：可溶，DMSO：可溶
• LogP：
  7.970 (est)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  10.3
• 重原子数：
  44
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,3'S,5R,5'R)-3,3'-二羟基-kappa,kappa-胡罗卜素-6,6'-二酮 在 aluminum tri-tert-butoxide 作用下， 以 苯 为溶剂， 反应 45.0h， 生成 (5R,,5'R)-Capsorubon
  参考文献：
  名称：

  合成天然植物，天然胡萝卜素和天然植物。X.合成冯（3 - [R，3'小号，5' - [R）-Capsanthin，（3小号，5 - [R，3'小号，5' - [R）-Capsorubin，（3'小号，5' - [R）-Kryptocapsin UND einigen Verwandten Verbindungen。Ein neuer Zugang zu optisch aktivenFünfring-Carotinoidbausteinendurch Hydroborierung †

  摘要：

  光学活性天然类胡萝卜素和结构相关化合物的合成。的X.合成（3 - [R，3'小号，5' - [R）-Capsanthin，（3小号，5 - [R，3'小号，5' - [R）-Capsorubin，（3'小号，5' - [R）-Cryptocapsin，和一些相关化合物。Hydroboraton用于光学活性五元环类胡萝卜素构建单元的新方法

  DOI：

  10.1002/hlca.19830660706
• 作为产物：
  描述：

  D-樟脑酸 在 钌 吡啶 、 chromium(VI) oxide 、 氢氧化钾 、 sodium hydroxide 、 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 五氯化磷 、 硫酸 、 甲基安非他命 、 水 、 氢气 、 氧气 、 臭氧 、 溶剂黄146 、 过碘酸 、 锌 作用下， 以 甲醇 、 乙醚 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 268.42h， 生成 (3S,3'S,5R,5'R)-3,3'-二羟基-kappa,kappa-胡罗卜素-6,6'-二酮
  参考文献：
  名称：

  Bowden, Roy D.; Cooper, Robin D. G.; Harris, C. John, Journal of the Chemical Society. Perkin transactions I, 1983, # 7, p. 1465 - 1474

  摘要：

  DOI：

文献信息

• POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
  申请人：Wu Nian

  公开号：US20150157721A1

  公开（公告）日：2015-06-11

  The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.

  该发明包括化合物、制备方法和使用方法。这些化合物可能具有线性或环状的骨架，以及三个或四个附加的功能基团：一个或两个疏水化合物，包括固醇或“脂溶性”维生素，一个或两个亲水性聚合物，以及一个或两个碳水化合物。公开了一组具有中心骨架和三个附加功能基团的聚合物-碳水化合物共轭物，其中一个疏水性化合物不含类固醇酸。该共轭物可能以脂肪酸作为主要疏水载体，一个亲水性聚合物和一个碳水化合物。特定的功能基团可以根据在制备药物、化妆品、营养保健品等方面的具体应用而选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化，包括N-烷基化或O-烷基化，醚化，酯化和酰胺化化学过程。还可以选择各种连接剂连接骨架和功能基团之间，以修改载体或中心骨架以进行偶联反应并优化共轭物的性能。
• Total synthesis of capsanthin and capsorubin using Lewis acid-promoted regio- and stereoselective rearrangement of tetrasubsutituted epoxides
  作者：Yumiko Yamano、Masayoshi Ito

  DOI：10.1039/b710386g

  日期：——

  The synthesis of capsanthin 1 and capsorubin 2 was accomplished via the C(15)-cyclopentyl ketone 6 prepared by Lewis acid-promoted regio- and stereoselective rearrangement of the epoxy dienal 5.

  辣椒红素1和辣椒红素2的合成是通过路易斯酸促进环氧二烯基5的区域和立体选择性重排制备的C（15）-环戊基酮6完成的。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors
  申请人：Lockwood Samuel F.

  公开号：US20080293679A1

  公开（公告）日：2008-11-27

  Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.

  向正在接受COX-2抑制剂治疗的受试者施用类胡萝卜素，特别是黄质类胡萝卜素，或者是天然类胡萝卜素的类似物或衍生物，如虾青素、叶黄素、玉米黄质、莱科黄素、莱科菲或番茄红素，可能会减少与使用COX-2选择性抑制剂药物相关的不良副作用的至少一部分。这些类胡萝卜素，或者是其类似物或衍生物，可以在受试者开始接受COX-2选择性抑制剂药物治疗之前、同时或之后进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物治疗同时进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物组合在一起制成药物制剂，也可以单独施用。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者血清和血浆细胞膜中低密度脂蛋白和其他脂质的过氧化。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者发生有害的临床心血管事件的几率。
• [EN] POLYMER-CYCLODEXTRIN-LIPID CONJUGATES<br/>[FR] CONJUGUÉS POLYMÈRE-CYCLODEXTRINE-LIPIDE
  申请人：WU NIAN

  公开号：WO2016209732A1

  公开（公告）日：2016-12-29

  The invention comprises compounds, methods of making, and methods of using. A group of polymer-cyclodextrin-lipid conjugates having a center backbone and three or four appended functional groups are disclosed, wherein one of the hydrophilic components is cyclodextrin. The compounds may have a backbone with three or four appended functional groups: one or two lipophilic compounds including sterols or "fat soluble" vitamins or fatty acids, one or two hydrophilic polymer and one cyclodextrin. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the center backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.

  该发明涵盖了化合物、制备方法和使用方法。公开了一组具有中心骨架和三个或四个附加功能基团的聚合物-环糊精-脂质共轭物，其中一个亲水成分是环糊精。这些化合物可能具有一个带有三个或四个附加功能基团的骨架：一个或两个疏水化合物，包括甾醇或“脂溶性”维生素或脂肪酸，一个或两个亲水性聚合物和一个环糊精。特定的功能基团可以针对制备药物、化妆品、营养保健品等特定应用进行选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化，包括N-烷基化或O-烷基化，醚化，酯化和酰胺化化学过程。还可以选择各种连接剂连接中心骨架和功能基团，以修改载体或中心骨架用于偶联反应并优化共轭物的性能。